Beth Fand Incollingo

Administering chemotherapy concurrently with androgen deprivation therapy (ADT), rather than saving cytotoxic treatment until after progression, improves overall survival for men with hormone-sensitive metastatic prostate cancer

Treatment of stage III non-small cell lung cancer (NSCLC) with chemotherapy, radiation, and surgery has hit a plateau, and the key to improved outcomes will hinge on the testing of targeted therapies in clinical trials with more novel designs and better patient selection, according to a leading researcher.

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

Organization into large group practices will be a key way for urologists to successfully navigate a healthcare system that continues to be fraught with an enormous amount of change, a keynote speaker said during LUGPA's annual meeting in Chicago in November.

Poor nutritional status-specifically, a low level of serum albumin-is a predictor of complications following radical cystectomy for patients with bladder cancer

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

Tasquinimod, an experimental immunotherapy and anti-angiogenic agent, prolongs not just progression-free survival (PFS) but also overall survival (OS) in certain men with castration-resistant prostate cancer

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

Men who experience hot flashes because they are undergoing androgen-deprivation therapy for prostate cancer are not significantly helped by two treatments that alleviate that symptom in menopausal women, the results of a study show.

Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

Headlines from the June meeting of the American Society of Clinical Oncology (ASCO) in Chicago announced to the general public what oncologists and hematologists have known for more than two years: sporadic shortages of cancer drugs are forcing suboptimal treatment plans for patients, and government efforts have not filled the void.

Men with advanced prostate cancer who took the GnRH antagonist degarelix experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events than did those patients who took LHRH agonists.

Marincola made a bold move earlier this year when he left a longterm position as a tenured senior investigator at the National Institutes of Health (NIH), in Bethesda, Maryland, and moved nearly 7000 miles to the Middle East to build a research program at a private hospital in Qatar.

The phase III PREVAIL trial of enzalutamide in chemotherapy-naïve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival

With the recent approval of a first-in-class radioactive isotope as a treatment for prostate cancer, urologists have a new weapon in their rapidly growing arsenal of therapies designed to fight this disease.

Whether it involves the minutiae of preclinical studies or the broad perspective of group leadership, if the work concerns gynecologic oncology, Ronald D. Alvarez, MD, has likely tried it.

A cocktail of herbs and vitamins lowered PSA in more than a third of patients with biochemically recurrent prostate cancer, and thus may be a good alternative to observation in this population.

Research efforts are under way to improve the efficacy of hormone therapy in the management of advanced estrogen receptor-positive (ER) breast cancer, including new strategies for targeting the PI3K/ mTOR pathway.

Trastuzumab is the clear standard of care for firstline therapy for nearly all HER2-positive breast cancers, and the oncology community has come a long way toward understanding how best to use the drug.

Since the mid-1970s, Rakesh K. Jain, PhD, has pursued an interest in the role that tumor microenvironment plays in drug delivery and efficacy.

Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer, but studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.

An interview with Rakesh K. Jain, PhD, a cancer researcher focused on pathophysiology who helped establish the role of the tumor microenvironment in the treatment of cancer.

A grant from a pharmaceutical company is translating into a win for both the University Medical Center of Princeton at Plainsboro and its patients with cancer.

Biomarkers for sensitivity to etirinotecan pegol that are found in circulating tumor cells of breast cancer patients can be "reliably measured."

When Jimmie C. Holland, MD, conducts research, geriatric cancer patients are often her focus. Holland has studied telephone intervention as a way to monitor stress in patients aged 65 and older. She discussed the effort with OncologyLive.

An Interview With Jimmie C. Holland, MD, on her research and role in the development of a vital area of cancer care.

More and more, as the use of maintenance therapy increases, oncology nurses are tasked with monitoring how the strategy is working for specific patients.

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.